Search Results

You are looking at 111 - 120 of 444 items for :

  • "paclitaxel" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

pharmacokinetics of carboplatin and pralatrexate used in combination Contact: Marcela G. del Carmen, MD, MPH • 617-724-4800 • mdelcarmen@partners.org ClinicalTrials.gov Identifier: NCT01188876 Neoadjuvant Weekly nab-Paclitaxel (Abraxane) Plus

Full access

scientific peer-review process and are overseen by the ORP. NCCN studies funded through the grant mechanism are highlighted below. Neoadjuvant Weekly nab-Paclitaxel (Abraxane) Plus Carboplatin Followed by Doxorubicin Plus Cyclophosphamide With

Full access

Thomas Olencki

the combination of high-dose celecoxib and paclitaxel, cetuximab, and erlotinib. However, he noted that further research is needed to confirm early encouraging findings for these agents. The benefits of high-dose celecoxib ( Figure 1 ) and paclitaxel

Full access

Vinod Ravi, Eric M. Sanford, Wei-Lien Wang, Jeffrey S. Ross, Naveen Ramesh, Andrew Futreal, Shreyaskumar Patel, Phillip J. Stephens, Vincent A. Miller, and Siraj M. Ali

disease. The patient was initially treated with paclitaxel at 80 mg/m 2 weekly; however, he was unable to tolerate paclitaxel weekly without a treatment break. He was therefore maintained on paclitaxel at the 80 mg/m 2 dose, cycling 2 weeks on and 1 week

Full access

Margaret A. Tempero

-resistant, and patients suffer from debilitating cytokine-mediated symptoms.” Current Treatment of Metastatic Disease Remains Challenging First-line treatment regimens remain FOLFIRINOX and gemcitabine/albumin-bound nab-paclitaxel, and for patients with BRCA1

Full access

Min Huang, Joyce O’Shaughnessy, Jing Zhao, Amin Haiderali, Javier Cortes, Scott Ramsey, Andrew Briggs, Vassiliki Karantza, Gursel Aktan, Cynthia Z. Qi, Chenyang Gu, Jipan Xie, Muhan Yuan, John Cook, Michael Untch, Peter Schmid, and Peter A. Fasching

4 RCTs, carboplatin in 3 RCTs, and nab-paclitaxel, everolimus, and anthracycline in 1 RCT each. Different pCR definitions were used across trials, of which ypT0/is ypN0 was the most common. The characteristics of the included trials are listed in

Full access

Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem, Joseph Chao, Carlos Corvera, Prajnan Das, Crystal S. Denlinger, Peter C. Enzinger, Paul Fanta, Farhood Farjah, Hans Gerdes, Michael Gibson, Robert E. Glasgow, James A. Hayman, Steven Hochwald, Wayne L. Hofstetter, David H. Ilson, Dawn Jaroszewski, Kimberly L. Johung, Rajesh N. Keswani, Lawrence R. Kleinberg, Stephen Leong, Quan P. Ly, Kristina A. Matkowskyj, Michael McNamara, Mary F. Mulcahy, Ravi K. Paluri, Haeseong Park, Kyle A. Perry, Jose Pimiento, George A. Poultsides, Robert Roses, Vivian E. Strong, Georgia Wiesner, Christopher G. Willett, Cameron D. Wright, Nicole R. McMillian, and Lenora A. Pluchino

preoperative chemotherapy or surgery alone in patients with locoregional esophageal cancer. 61 – 67 Results from the multicenter phase III randomized CROSS trial, the largest trial in its class, showed that preoperative chemoradiation with paclitaxel and

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Mohammad Jahanzeb, Krystyna Kiel, Britt-Marie Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, George Somlo, Richard L. Theriault, Neal S. Topham, John H. Ward, Eric P. Winer, and Antonio C. Wolff

trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer . J Clin Oncol 2005 ; 23 : 3676 – 3685 . 94 Smith IE Dowsett M Ebbs SR . Neoadjuvant

Full access

Jonathan W. Riess, Seema Nagpal, Joel W. Neal, and Heather A. Wakelee

EGFR-activating mutation or an ALK translocation is doublet chemotherapy (category 1). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) currently list docetaxel, paclitaxel, pemetrexed, vinorelbine

Full access

Keith D. Eaton and Renato G. Martins

the NCIC trial had a median survival of 7.4 months, although it was 7.9 months for patients enrolled on ECOG 1594, a trial comparing 3 third-generation doublets with cisplatin and paclitaxel published 14 years later. 2 Several strategies have